Check for updates

OPEN ACCESS

EDITED BY Juan Manuel Mejia-Arangure, Universidad Nacional Autonoma de Mexico, Mexico

REVIEWED BY

Haydeé Rosas-Vargas, Instituto Mexicano del Seguro Social, Mexico Mariana Bohns Michalowski, Federal University of Rio Grande do Sul, Brazil

*CORRESPONDENCE Maria S. Pombo-de-Oliveira mpombo@inca.gov.br; masocspoliveira@gmail.com.br

RECEIVED 07 August 2023 ACCEPTED 31 October 2023 PUBLISHED 29 January 2024

CITATION

de Carvalho VM, Chung-Filho AA, Braga FHP, Chagas-Neto P, Soares-Lima SC and Pombo-de-Oliveira MS (2024) Interaction between birth characteristics and *CRHR1*, *MC2R*, *NR3C1*, *GLCCI1* variants in the childhood lymphoblastic leukemia risk. *Front*. *Oncol*. 13:1274131. doi: 10.3389/fonc.2023.1274131

COPYRIGHT

© 2024 de Carvalho, Chung-Filho, Braga, Chagas-Neto, Soares-Lima and Pombo-de-Oliveira. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Interaction between birth characteristics and *CRHR1, MC2R, NR3C1, GLCCI1* variants in the childhood lymphoblastic leukemia risk

Vitoria Müller de Carvalho ¹, Alython Araujo Chung-Filho ¹, Flávio Henrique Paraguassu Braga ², Paulo Chagas-Neto¹, Sheila Coelho Soares-Lima ¹ and

Maria S. Pombo-de-Oliveira 101* for EMiLi Study Group

¹Research Center, Molecular Carcinogenesis Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil, ²National Placental and Umbilical Cord Blood Bank, Instituto Nacional de Câncer (INCA), Ministério da Saúde (MS), Rio de Janeiro, Brazil

Background: The incidence rate of childhood acute lymphoblastic leukemia (ALL) differs worldwide, and the interplay between hemostasis actors and the maladaptive responses to environmental exposures has been explored. It has been proposed that endogenous cortisol, induced by different triggers, would eliminate pre-leukemic clones originated *in utero*. Herein, we tested if the interaction between *CRHR1rs242941 C>A*, *MC2Rrs1893219 A>G*, *NR3C1rs41423247 G>C*, and *GLCC11rs37972 C>T* (players in glucocorticoid secretion) and birth characteristics would be associated with ALL risk.

Methods: Children aged <10 years were enrolled within the EMiLI project (period: 2012 to 2020). The study had three steps: (1) observational analysis of birth characteristics (n = 533 cases and 1,603 controls); (2) genotyping to identify single-nucleotide variants (n = 756 cases and 431 controls); and (3) case-only to test gene-environment interactions (n = 402 cases). Genetic syndromes were exclusion criteria. The controls were healthy children. The distribution of the variables was assessed through Pearson's chi-square test. Logistic regression (LR) tests were run fitted and adjusted for selected covariate models to estimate the association risk. Formal interaction analysis was also performed. Genotyping was tested by qPCR with TaqMan probes (*NR3C1*) or by high-resolution melting (*MC2R* and *GLCCI1*). Hardy–Weinberg equilibrium (HWE) was accessed by the chi-square test. The genotype–risk association was tested in co-dominant, dominant, and recessive models. The gene–environment interaction odds ratio (iOR) was assessed in case-only.

Results: Low birthweight, C-section, and low maternal schooling were associated with increased risk for ALL, adjOR 2.11, 95% CI, 1.02–4.33; adjOR 1.59, 95% CI, 1.16–2.17; and adjOR 3.78, 95% CI, 2.47–5.83, respectively, in a multiple logistic regression model. *MC2R* rs1893219 A>G was negatively associated with ALL (AG: OR = 0.68; 95% CI = 0.50–0.94 and GG: OR = 0.60; 95% CI = 0.42–0.85), while for *GLCCI1* rs37972 C>T, TT was positively associated

with ALL (OR = 1.91; 95% CI = 1.21–3.00). The combination of genotypes for MC2R (AA) and GLCC/1 (TT) increased ALL risk (OR = 2.61; 95% CI = 1.16–5.87). In a multiplicative interaction, MC2R rs1893219 A>G was associated with children whose mothers had less than 9 years of schooling (iOR = 1.99; 95% CI = 1.11–1.55).

Conclusion: Our study has demonstrated a significant association between *MC2R* rs1893219 A>G (reduced risk) and *GLCC11* rs37972 C>T variants (increased risk) and childhood ALL susceptibility. Based on this evidence, genes controlling the HPA axis activity may play a role in leukemogenesis, and further investigation is needed to substantiate our findings.

KEYWORDS

MC2R rs1893219 A>G, GLCCI1 rs37972 C>T, acute lymphoblastic leukemia, interaction, Brazil

1 Introduction

The causal mechanism for leukemia gathers environmental factors, inherited susceptibility from polygenic variants, and chances of interactions. Models for interplay of such chances have been proposed for childhood acute lymphoblastic leukemia (ALL) mainly concerning B-cell precursor-ALL (Bcp-ALL), in which chromosomal translocations can arise in utero (1-3). Greaves and collaborators have unraveled the clonal evolution of Bcp-ALL endorsing the model of multiple gene-environment factors in the causal mechanisms of ALL pathogenesis (4-6). One of the pillars supporting the Greaves hypothesis is the epidemiological association of birth characteristics, the first year of the child's life hygiene and socialization, as well as immune responses to early infections (3, 7). This biological evidence has opened avenues to the so-called "adrenal hypothesis" that has also emerged from observational studies of global differences on ALL incidence rate and environmental exposures in less developed societies (8). These differences led to the speculation that the hypothalamic-pituitaryadrenal (HPA) axis decreases the kinetics of disappearance of preleukemic clone through qualitative and quantitative plasma cortisol levels in populations with deprivation and infection exposures (8). Differences in the reactivity of the HPA axis have been proposed at genomic levels and its setting occurs during the intrauterine life, although it can also be reset by stressful experiences in early life or chronic stress as individuals go through threatening experiences (9, 10).

Physiologically, cortisol and cortisone, the so-called endogenous glucocorticoids (GCs), are released according to a cascade of interacting signals and actions from different organs of the HPA axis, initiated by corticotrophin-releasing hormone (CRH). CRH acts through the interaction with the CRHR1 receptor in the hypothalamus, leading to the release of the adrenocorticotropic hormone (ACTH). In the adrenal cortex, ACTH binds its receptor MC2R (melanocortin type 2 receptor), stimulating cortisol secretion. Cortisol will ultimately bind to its receptor NR3C1 (receptor nuclear subfamily 3, group C, member 1) in the target cell and stimulate the expression of target genes (11, 12). Glucocorticoid Induced 1 (*GLICCI1*) is one of these genes and, although its functions are not completely elucidated, it seems to both modulate glucocorticoid efficiency and regulate apoptosis (13). Based on their key functions in the HPA axis as well as on our interest of evaluating the different steps in this pathway, *CRHR1*, *MC2R*, *NR3C1*, and *GLICCI1* were selected to evaluate the possible contribution of genetic variants to the variability in GC secretion levels. The specific variants were selected based on their frequencies and on previous studies suggesting their association with GC-associated outcomes (14–16).

In addition, we have recently described the association between being born through Cesarean-section (C-S), being the first child, and low birth weight (LBW) with increased risk for ALL, although the biological plausibility remains speculative and deserve further studies (17). Researchers claim that mode of delivery through C-S and children with LBW would present low epinephrine, cortisol, and cytokine levels, elements necessary to establish a healthy microbiome and a harmonic immune system (10). Herein, we hypothesized that gene variants may impact the GCs' endogenous levels, subsequently allowing the expansion of possible leukemic clone that arose *in utero*, contributing to ALL development. Therefore, the aim of the study was to investigate whether ALL risk is associated with child's birth characteristics and genetic susceptibility involving the HPA axis.

2 Materials and methods

2.1 Study design and subjects

Children with less than 10 years of age at diagnosis of Bcp-ALL and T-ALL, from a hospital-based case-control study, were included over the period of 2012 to 2020. The present study was part of the project "Epidemiology of Multi-institutional Study Group of Acute Leukemia (EMiLI)", for which the enrollment of cases and controls was recently fully described (17). Herein, the analysis was carried out in three steps:

- (1) Case-control study (n = 2136) to revisit the birth characteristic's risk estimate adjusted by maternal schooling. The variables for the models included leukemia subtypes (484 Bcp-ALL and 49 T-ALL), race/ethnicity, child sex, mode of child delivery, and birth weight, while maternal age at childbirth and maternal schooling were the covariates. The maternal schooling was assessed as a proxy for the child's socioeconomic level.
- (2) Genotyping study. Genomic DNA from cases (n = 756) and controls (n = 431) was obtained from peripheral blood cells, using the salting-out method (15). To identify CRHR1 rs242942 C>T, MC2R rs1893219, and GLCCI1 rs37972 C>T variants, polymerase chain reactions followed by highresolution melting (HRM) were performed. The oligonucleotides were designed to each region of interest and the protocol conditions are shown in Supplementary Table 1. Approximately 10 to 15 samples genotyped for each variant were randomly selected to validate the HRM results using Sanger direct sequencing. The electropherogram analysis was performed using the Mutation Survey software (SoftGenetics, Pennsylvania, USA). NR3C1 rs41423247 G>C allelic discrimination was performed using a TaqMan assay (C:86507873_10, Thermo Fisher) and TaqMan Genotyping Master MixTM (Thermo Fisher), in Rotor-gene 6000 (QIAGEN, Germany). The variables included in this step of the study were leukemia subtypes, racial/ethnicity, child sex, allele status, and genotype frequencies.
- (3) Case-only. In this step, the impact of the multiplicative interaction between genotypes and environmental exposures on ALL risk was estimated (18). For this, cases with and without the risk allele were compared with respect to exposure (19). The validity of this design to estimate the interaction odds ratio (IOR) depends on the assumption that among controls, genotype and exposure are independent, i.e., the fact of having the gene variant will not influence the exposure variable.

2.2 Statistical analysis

The sample size was calculated considering controls per case (ALL subtypes; ratio: 1:3), $\alpha = 0.05$, $\beta = 0.2$ for power = 0.80. To explore the impact of the birth characteristics (C-S and LBW) considering the hypothesis of the intrauterine origin of ALL and the peak incidence, we have stratified the cases into two age strata: (1) children who were up to 5 years of age and (2) children aged older than 6 up to 10 years at the diagnosis. The association between C-S and LBW and ALL risk was estimated using multiple logistic regression (MLR) adjusted for the mother's age at childbirth [adjusted odds ratio (adjOR) and 95%

confidence interval (95% CI)]. The core model with variables of interest consisted of mode of delivery (C-S vs. vaginal), child's ethnicity (White versus multiracial, as reference), birth weight [\leq 2,500, 2,500 to 3,500 (reference); >3,550], gestational age (<37; \geq 37 weeks), maternal ages [<25; 25–34 (reference); \geq 35 years old], and maternal schooling (\leq 9, >9 years).

Genotyping: The genotype frequency distribution in controls was analyzed to test the Hardy–Weinberg equilibrium (HWE) by Pearson's χ^2 test; p > 0.05 was in accordance with HWE. Frequency differences between cases and controls were assessed through logistic regression test, the OR and 95% CI were calculated in the codominant (heterozygous versus wild type and variant homozygous versus wild type), dominant (variant homozygous + heterozygous versus wild type), and recessive (variant homozygous versus heterozygous + wild type) models. Variants associated with ALL risk were also analyzed for gene–gene interactions. In the additive model, the relative excess risk due to interaction (RERI), attributable proportion (AP), and synergy index (SI) were measured. These values and their respective deltamethod 95% CI were calculated as published by Anderson et al. (20).

Case-only: We used unconditional logistic regression to calculate the IOR 95% CI controlled by the child's ethnicity (Whites as reference). Only genetic variants associated with ALL risk in step 2 were included in the model, and the non-risk alleles were used as reference. The risk factors analyzed included the mode of delivery (vaginal as reference), birth weight (2,500–3,499 as reference), and mother education (>9 years as reference). All statistical analyses were performed using R studio version R4.1.1 and IBM SPSS Statistics version 26.

Ethical aspects: All collaborating Brazilian institutions approved the study and written informed consents were obtained from mothers or relatives responsible for the enrolled children. The Ethics and Scientific Committees of Instituto Nacional de Cancer approved this study (INCA/CAEE #626.268; CEP/CONEP 1.394.043).

3 Results

3.1 Birth characteristics

In this study, a total of 2,136 children, including 533 ALL cases and 1,603 controls, were included in the initial phase. The case:control ratio was 1:3. Among cases, 484 (90.8%) were Bcp-ALL and 49 (9.2%) were T-ALL (Table 1). Most cases were children up to 5 years of age at diagnosis (mean age: 3.5 years). Missing information (MI) was less than 4.7% for both cases and controls in the variables of interest, notably mode of delivery, birth weight, and maternal age. Cases' mothers have reported lower schooling than controls (p = 0.001). The proportion of mode of delivery was similar between the groups, while LBW (\leq 2,500) was more prevalent among ALL cases (p = 0.001).

In the multiple logistic regression model (Table 2), both in the crude analysis and after adjustment by maternal age, LBW, C-section, and low maternal schooling were associated with increased risk for ALL, adjOR 2.11, 95% CI, 1.02–4.33; adjOR 1.59 95% CI, 1.16–2.17; and adjOR 3.78, 95% CI, 2.47–5.83, respectively.

TABLE 1 Distribution of variable frequencies of 533 acute lymphoblastic leukemia and their 1603 controls.

Variables	Total N, 2136 (%)	Cases N, 533 (%)	Controls N, 1603 (%)	p value
Leukemia Subtypes				
BCP-ALL	-	484 (90.8)	-	
T-ALL	-	49 (9.2)	-	
Child's age (years)				0.001
0-5	1570 (73.5)	431 (80.9)	1139 (71.1)	
≥ 6	566 (26.5)	102 (19.1)	464 (28.9)	
Mean (min-max) SD	3.7 (0.0-10) 2.8	3.5 (0.0-10) 2.5	3.0 (0.0-10) 2.9	
Sex				0.85
Females	950 (44.5)	239 (44.8)	711 (44.4)	
Males	1186 (55.5)	294 (55.2)	892 (55.6)	
Child's Ethnicity				0.99
Whites	1058 (49.5)	264 (49.5)	794 (49.5)	
Multiracial	1078 (50.5)	269 (50.5)	809 (50.5)	
Mode of delivery				0.60
Vaginal	976 (45.7)	242 (45.4)	734 (45.8)	
C-Section	1157 (54.2)	291 (54.6)	866 (54.0)	
MI	3 (0.1)	0 (0.0)	3 (0.2)	
Birth Weight (grams)				0.001
≤ 2500	87 (4.1)	40 (7.5)	47 (2.9)	
2501-3500	1246 (58.3)	323 (60.6)	923 (57.6)	
> 3500	777 (36.4)	145 (27.2)	632 (39.4)	
MI	26 (1.2)	25 (4.7)	1 (0.1)	
Mean (min-max) SD	3362(1153-6125) 492,1	3250(1153-5200) 523,6	3398(1805-6125)473,2	
Maternal Schooling (years)				0.001
< 9	223 (10.4)	139 (26.1)	84 (5.2)	
≥ 9	1413 (66.1)	375 (70.4)	1038 (64.8)	
MI	500 (23.4)	19 (3.5)	279 (17.4)	
Mean (min-max) SD	10.7 (0.0-26) 3.48	10.9 (0.0-26) 4.29	10.6 (0.0-25) 3.03	
Maternal age				0.001
< 25	783 (36.7)	228 (42.8)	555 (34.6)	
25-34	1009 (47.2)	228 (42.8)	781 (48.7)	
≥ 35	325 (15.2)	64 (12.0)	261 (16.3)	
MI	19 (0.9)	13 (2.4)	6 (0.4)	
Mean (min-max) SD	27.1 (13.0-51.0) 6.2	26.3 (13.0-43.0) 6.8	27.0(18.0-51.0) 6.1	

BCP-ALL, B-cell acute lymphoblastic leukemia; T-ALL, T-cell Lymphoblastic Leukemia; N, number; MI, missing information; SD, standard deviation; Min, minimum; max, maximum. Brazil, 2012-2020.

Variables	ALL N = 492 (%)	Controls N = 1,106 (%)	Crude OR 95% Cl	<i>p</i> -value	adj OR 95%CI	<i>p</i> -value
Child's ethnicity	,					
White	250 (50.8)	559 (50.5)	1.00*		1.00*	
Multiracial	242 (49.2)	547 (49.5)	0.91 (0.73-1.13)	0.400	1.11 (0.82–1.50)	0.514
Birth weight (g)						
≤2,500	36 (7.3)	24 (2.2)	2.87 (1.64-4.91)	0.001	2.11 (1.02-4.33)	0.044
2,501-3,500	313 (63.6)	635 (57.4)	1.00*		1.00*	
>3,550	143 (29.1)	447 (40.4)	0.65 (0.51-0.83)	0.001	0.45 (0.32–0.65)	0.002
Mode of deliver	У					
Vaginal	226 (45.9)	547 (49.5)	1.00*		1.00*	0.004
C-section	266 (54.1)	559 (50.5)	1.14 (0.92–1.43)	0.230	1.59 (1.16–2.17)	
Maternal schoo	ling (years)					
<9	129 (26.2)	84 (7.6)	4.22 (3.12-5.72)	0.001	3.78 (2.47-5.83)	0.001
≥9 (ref)	363 (73.8)	1,022 (92.4)	1.00*		1.00*	

TABLE 2 Multiple logistic regression-derived odds ratio for childhood acute lymphoblastic leukemia and their controls and environmental exposure.

All variables are in the model; Unconditional analysis; C-section and birthweight adjusted by maternal age, ALL, acute lymphoblastic leukemia; *, reference. Brazil, 2012–2020. g, grams; n, number; OR, odds ratio; C-section, Cesarean section; 1.00*, reference group.

3.2 Genotyping

A total of 756 cases and 431 controls were genotyped for *CRHR1rs242941 C>A*, *MC2Rrs1893219 A>G*, *NR3C1rs41423247 G>C*, and *GLCC11rs37972 C>T* variants, using only samples of optimal DNA quality (Table 3). There was no statistically significant difference between

cases and controls regarding the variables included in the models. The controls' genotypic frequencies for all variants were in HWE. A null result was found regarding the variants *CRHR1*rs242941 C>A and *NR3C1*rs41423247 G>C in all models assessed, while *MC2R* rs1893219 A>G and *GLCCI1* rs37972 C>T were associated with genetic predisposition to ALL development (Table 4). *MC2R* rs1893219 A>G

TABLE 3 Main characteristics and frequencies of gene variants of acute lymphoblastic leukemia and controls.

Variables		ALL N = 756 (%)	Controls N = 431 (%)	p-value
Sex				
	Male	428 (56.6)	233 (54.1)	0.39
	Female	328 (43.4)	198 (45.9)	
Race/skin color				
	Multiracial	407 (53.8)	240 (55.7)	0.53
	White	349 (46.2)	191 (44.3)	
ALL subtypes				
	BCP-ALL	654 (86.5)	-	-
	T-ALL	102 (13.5)	-	
Variant frequencies*				
	CRHR1 rs242941 C>A	0.38	0.40	-
	MC2R rs1893219 A>G	0.48	0.55	
	NR3C1 rs41423247 G>C	0.23	0.23	
	GLCCI1 rs37972 C>T	0.37	0.32	

N, number; ALL, acute lymphoblastic leukemia includes T-cell ALL and B-cell precursor ALL; NA, not applicable; (*) the Hardy–Weinberg equilibrium was tested for CRHR1, MC2R, NR3C1, and GLCC11. p-values = 0.70, 0.50, 0.18, and 0.50, respectively, among the control group. Brazil, 2012–2020.

showed an inverse association in models adjusted by race (DM: adjOR, 0.65, 95% CI, 0.48–0.87), demonstrating a significant protective role, while *GLCCI1 rs37972 C>T* was positively associated in the recessive model (RM) (adjOR, 1. 64, 95% CI, 1.11–2.43). The analysis according to race, sex, ALL subtypes, and age strata are shown in the Supplementary Material. Among white children, the *MC2Rrs*1893219 A>G variant was negatively associated with ALL in the dominant model (DM) (OR, 0.58, 95% CI, 0.38–0.88) while *GLCCI1rs37972 C>T* was positively associated in the RM (OR, 1.83, 95% CI, 1.01–3.34) (Supplementary Table 2). The same risk association pattern was found in Bcp-ALL and T-ALL subtypes (Supplementary Table 3) and among male children (Supplementary Table 4).

The combination of wild-type homozygous genotype for *MC2R* (AA) and variant homozygous genotype for *GLCCI1* (TT), risk genotypes for the respective genes, showed a stronger association

with ALL if compared to the individual effect of each variant (OR = 2.61; 95% CI = 1.16-5.87). The sum of the interaction analysis shown in Figure 1, however, revealed no synergistic or inhibitory effect between the variants (RERI, 0.26; 95% CI, -2.01-2.54).

3.3 Epidemiologic-genotyping assessment

Finally, the effect of *MC2R* rs1893219 A>G AA and *GLCC11* rs37972 C>T was tested for interactions with birth weight, mode of delivery, and maternal education (Table 5). The model adjusted by race did not show interaction with *GLCC11* rs37972 C>T risk, although an estimate risk factor was attributed to children with mothers of less than 9 years of schooling (iOR, 1.86, 95% CI = 1.06-3.26; Adj OR, 1.99; 95% CI = 1.11-3.55).

TABLE 4	Gene variants	and the	genetic	predisposition	risks in	acute l	ymphoblastic leuk	emia.

Genotype	Cases n (%)	Controls n (%)	Crude OR (95% CI)	AdjOR (95% CI)	<i>p</i> -value
CRHR1 rs242941 C>A	683 (100)	379 (100)			
CC	264 (38.7)	136 (35.9)	1.0*		
CA	315 (46.1)	185 (48.8)	0.88 (0.67–1.16)	0.89 (0.68–1.18)	0.42
АА	104 (15.2)	58 (15.3)	0.92 (0.63-1.35)	0.80 (0.56-1.14)	0.22
DM			0.89 (0.68–1.15)	0.94 (0.64–1.37)	0.74
RM			0.99 (0.70-1.41)	1.01 (0.71-1.43)	0.97
<i>MC2R</i> rs1893219 A>G	608 (100)	401 (100)			
AA	180 (29.6)	85 (21.2)	1.0*		
AG	275 (45.2)	192 (47.9)	0.68 (0.49-0.93)	0.68 (0.50-0.94)	0.02
GG	153 (25.2)	124 (30.9)	0.58 (0.41-0.83)	0.60 (0.42-0.85)	<0.001
DM			0.64 (0.48-0.86)	0.65 (0.48–0.87)	< 0.001
RM			0.75 (0.57–0.99)	0.76 (0.57–1.00)	0.05
NR3C1 rs41423247 G>C	693 (100)	407 (100)			
GG	410 (59,2)	244 (60.0)	1.0*		
GC	243 (35,1)	136 (33.4)	1.06 (0.82–1.38)	1.05 (0.81–1.37)	0.71
CC	40 (5,8)	27 (6.6)	0.88 (0.53-1.47)	0.88 (0.52–1.47)	0.62
DM			1.03 (0.81–1.33)	1.02 (0.80–1.31)	0.86
RM			0.86 (0.52-1.43)	0.85 (0.51-1.41)	0.52
GLCCI1 rs37972 C>T	678 (100)	410 (100)			
CC	273 (40.3)	187 (45.6)	1.0*		
СТ	305 (45.0)	184 (44.9)	1.14 (0.87–1.47)	1.13 (0.87–1.47)	0.35
ТТ	100 (14.7)	39 (9.5)	1.76 (1.16–2.66)	1.75 (1.16–2.65)	0.01
DM			1.24 (0.97–1.59)	1.24 (0.97–1.59)	0.09
RM			1.65 (1.11–2.44)	1.64 (1.11–2.43)	0.01

n, number; OR, odds ratio; 95% CI, 95% confidence interval; RM, recessive model; DM, dominant model; AdjOR, adjusted odds ratio by race. *, reference group.



A graphic plot summarizing the effect of the interaction of *MC2R* rs1893219 and *GLCCI1* rs37972 variants in acute lymphoblastic leukemia risk. The association between genotypic combinations of the *MC2R* rs1893219 A>G and *GLCCI1* rs37972 C>T variants tested with adjusted odd ratio (adjOR) 95% confidence interval (CI) by race; GG+AG/TT, genotype of protection risk; AA/CC+TT, genotype of protection risk, AA+TT, genotype of high risk. The relative excess risk in the additive model was RERI=0.26 (-2.01-2.54), AP, attributable proportion=0.10 (-0.70-0.90) and SI, synergy index=1.19 (0.7-5.19) (20).

4 Discussion

This is the first study that explores the HPA axis and childhood ALL through the effect of germline variants and a gene– environment interaction study model (8, 19). In the observational assessment, LBW, C-S, and low maternal schooling were positively associated with ALL risk. Worldwide, low education level is a proxy for socioeconomic status, and it has been associated with the functioning of the maternal HPA axis during pregnancy, impacting the health of the fetus. In populations with low human development index (HDI), LBW was associated with higher maternal cortisol levels at pregnancy, in turn leading to an LBW offspring with severe GC secretion deficiency (21, 22). However, the impact of gene variants in the HPA axis function has not been fully assessed. Within the complexity of ALL multifactorial etiopathogenesis, a role for genetic susceptibility involving genes responsible for GCs' secretion cannot be dismissed (8, 23, 24).

This study focused on *CRHR1*, *MC2R*, *NR3C1*, and *GLICCI1*, four genes within the HPA axis, and the association of their variants with C-S, birthweight, and ALL. *CRHR1* and *NR3C1* variants did not show any association with birth weight and ALL. This result is in line with Schneider et al. (2020), who have found no association between genetic variants in the GC receptor gene and LBW (25). However, *NR3C1* seems to be crucial to the induction of apoptosis

TABLE 5	Case-only	analysis of ge	ene-environment	interaction	for MC2R	rs1893219	A>G and	GLCCI1	rs37972	C>T
---------	-----------	----------------	-----------------	-------------	----------	-----------	---------	--------	---------	-----

Variable	MC2R rs1893219 A>G n = 323				GLCCl1 rs37972 C>T n = 348					
	AA, n (%)	AG+GG, n (%)	iOR (95% CI)	AjiOR	<i>p-</i> value	TT, n (%)	CC+CT, n (%)	iOR (95% CI)	AjiOR	<i>p-</i> value
Birth weigł	nt (g)									
2,501– 3,500	53 (66.3)	113 (57.1)	1.0*	1.0*		30 (62.5)	172 (62.5)	1.0*	1.0*	
≤2,500	9 (11.2)	11 (5.5)	2.05 (0.80-5.24)	2.15 (0.84– 5.54)	0.11	3 (6.3)	22 (8.0)	0.78 (0.22-2.78)	0.78 (0.22– 2.77)	0.70
>3,500	18 (22.5)	74 (37.4)	0.61 (0.33-1.12)	0.59 (0.32– 1.09)	0.09	15 (31.2)	81 (29.5)	1.06 (0.54–2.08)	1.05 (0.54– 2.07)	0.88
Mode of de	elivery									
Vaginal	44 (49.4)	97 (41.5)	1.0*	1.0*		20 (39.2)	132 (44.4)	1.0*		
C-Section	45 (50.6)	137 (58.5)	0.72 (0.44-1.18)	0.72 (0.44– 1.18)	0.20	31 (60.8)	165 (55.6)	1.24 (0.68–2.28)	1.23 (0.67– 2.26)	0.50
Maternal e	Maternal education									
≥9 years	56 (67.5)	177 (79.4)	1.0*	1.0*		38 (76.0)	207 (74.2)	1.0*	1.0*	
<9 years	27 (32.5)	46 (20.6)	1.86 (1.06-3.26)	1.99 (1.11– 3.55)	0.02	12 (24.0)	72 (25.8)	0.91 (0.45–1.83)	0.93 (0.46– 1.88)	0.83

n, number; iOR, interaction odds ratio; AjiOR, interaction odds ratio adjusted for race/ethnicity; 95% CI, 95% confidence interval. Brazil, 2012–2020. *, reference group.

mediated by GCs in lymphoblasts and its regulation is essential in ALL treatment. Therefore, the null results found here regarding the risk association with ALL do not exclude its relevance in investigations related to resistance to GC therapy.

MC2R, another key receptor in the HPA axis, is much less studied. The variant MC2R rs1893219 A>G, mapped to MC2R promoter region, is the most frequent variant (44%) worldwide and has been previously associated with decreased risk of cerebral hemorrhage and with clinical outcomes in ALL (15). In addition, the MC2R rs1893219 A>G variant was associated with better response to glucocorticoid treatment in infantile spasms (23). Herein, the MC2R rs1893219 A>G variant was found inversely associated with the risk of childhood ALL in both subtypes (Bcp-ALL and T-ALL), and a gene-environment interplay was observed in children whose mothers had low schooling. Low education is an important risk factor for the mother and the newborn, being associated with infant mortality, less prenatal care, preterm delivery, LBW, and lower breastfeeding (26-28). Since several of these characteristics are associated with maternal stress, they could lead to increased GC levels in the intrauterine environment (29, 30) . Therefore, these potential variations in GC production by the mother together with the potential modulation of MC2R expression levels by its genetic variant could affect the development and the response of the HPA axis in the fetus and modulated ALL risk.

Interestingly, the genetic variant of GLCCI1, another gene less explored in the literature, was positively associated with ALL risk. A literature review discloses only 52 articles exploring this gene, and the great majority evaluated the role of GLICC1 in the treatment response of inflammatory and immunological diseases (31). No studies in leukemias were found, even though GCs are crucial for ALL treatment and relapse prediction (32). The effects of GCs on lymphocytes are translated by the reduction of peripheral circulating lymphocytes through interaction with the GC receptor (GR). Initially, GlCCI1 was described to bind to specific GRs in the cytoplasm forming complexes and being transferred to the nucleus, thus regulating the transcriptional activity of GC response genes (33). However, recently, Kiuchi and colleagues showed that GLCCI1 is an early marker of apoptosis in murine thymocytes (34), corroborating the study of Tantisira and collaborators (14). In this context, since GLCCI1 rs37972 C>T leads to lower gene expression, a reduction of apoptosis of inflammatory cells is expected to take place. Thus, based on the biological mechanisms summarized above, we hypothesize that the effect of GLCCI1 rs37972 C>T in B and T cells in concert with environmental factors could facilitate the expansion of clonal cells of intrauterine origin. This is in accordance with the biological network proposed by Greaves and the adrenal hypothesis proposed by Schmiegelow regarding less fortunate societies and ALL incidence rates (3, 8).

Although the results found here are novel and shed light on the etiopathogenesis of ALL of intrauterine origin, limitations include the lack of knowledge of the functional effects of all genetic variants analyzed as well as the lack of evaluation of known environmental risk factor for ALL development, such as exposure to ionizing radiation and pesticides. Moreover, we encourage further research to explore additional common variants in the HPA axis pathway along with other modulators of the immune response, such as the history of early-life infections.

5 Conclusion

Our study has demonstrated a significant association between *MC2R*rs1893219 A>G (protective) and *GLCCI1* rs37972 C>T variants (increased risk) and childhood ALL susceptibility. Based on these lines of evidence, genes controlling the HPA axis activity may play a role in leukemogenesis and further investigation is needed to substantiate our findings.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Ethics statement

The studies involving humans were approved by National Cancer Institute Ethics Committee: CEP/CONEP:1.394.043. The studies were conducted in accordance with the local legislation and institutional requirements. Written informed consent for participation in this study was provided by the participants' legal guardians/next of kin.

Author contributions

VMC: conceptualization, methodology, formal analysis, writing the original draft, reviews, and editing. AACF: methodology, statistical analysis and writing the original draft, reviews. PCN: data curation, statistical analysis. FHPB: collaboration, data curation, reviews the manuscript. SCSL: conceptualization, methodology, formal analysis, writing and reviews. MSPO: conceptualization, data curation, writing and editing, funding acquisition. All authors contributed to the article and approved the submitted version.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This work was supported by grants from *Conselho Nacional de Desenvolvimento Científico e Tecnológico* (CNPq #481104/2012-7), *Fundacção de Amparo à Pesquisa do Estado do Rio de* Janeiro (FAPERJ, E-26/110.712/2012), and TUCCA-*Associacção para Criancças e Adolescentes com Cancer*, São Paulo, Brazil. MP is supported by CNPq [#310877/2019-9], FAPERJ CNE #E-26/102.337/2013; CNE #E-26/202.577-2019; SC is supported by E-26/200.256/2023.

Acknowledgments

We thank the EMiLI Study participants who sent samples and clinical information: Alayde V. Wanderley and André S. Khavat (Belém, Pará); Carolina Iracema O. Rego and Patricia C. de Brito (Goiaênia, Góias); Isis M. Q. Magalhães (Distrito Federal); George S. Freitas-Junior (Cuiabá, Mato Grosso); Everaldo Ruiz-Junior (Goiaênia, Goiás); Rosania M. Basegio (Campo Grande, Mato Grosso do Sul); Andrea G. Nobrega (João Pessoa, Paraiba); Teresa Cristina C. Fonseca, Regiana Q. de Souza, and Fabia Idalina R. Neves (Itabuna, Bahia); Luciana N. Silva and Juliana Teixeira Costa (Salvador, Bahia); Ana Maria Marinho (Salvador, Bahia); Mauricio de Souza Meira (Feira de Santana, Bahia); Eda Manzo and Claudia Teresa de Oliveira (Jahu, São Paulo); Sidnei Epelman and Renato P.G. Oliveira (São Paulo, São Paulo); Gustavo R. Neves (Sorocaba, São Paulo, São Paulo); Lilian M. Cristofani (São Paulo, São Paulo); Patricia C. Lima (Chapecó, Santa Catarina); Imarui Costa (Florianópolis, Santa Catarina); and Mariana B. Michalowski, Adriano N.R. Taniguchi, and Rebeca F.Marques (Porto Alegre, Rio Grande' do Sul). We are also grateful to Eugenia Terra-Granado, Carolina Zampier, Bruno Aguiar, Gisele M. de Vasconcelos, Filipe V.S. Bueno, Yngrid Cabral, Paula Vieira, Elissa Morgado, and Kathleen Araújo for technical support in the laboratory.

References

1. Enciso-Mora V, Hosking FJ, Sheridan E, Kinsey SE, Lightfoot T, Roman E, et al. Common genetic variation contributes significantly to the risk of childhood B-cell precursor acute lymphoblastic leukemia. *Leukemia* (2012) 26:2212–5. doi: 10.1038/ leu.2012.89

2. Evans T-J, Milne E, Anderson D, de Klerk NH, Jamieson SE, Talseth-Palmer BA, et al. Confirmation of childhood acute lymphoblastic leukemia variants, ARID5B and IKZF1, and interaction with parental environmental exposures. *PloS One* (2014) 9: e110255. doi: 10.1371/journal.pone.0110255

3. Greaves M. A causal mechanism for childhood acute lymphoblastic leukaemia. *Nat Rev Cancer* (2018) 18:471–84. doi: 10.1038/s41568-018-0015-6

4. Swaminathan S, Klemm L, Park E, Papaemmanuil E, Ford A, Kweon S-M, et al. Mechanisms of clonal evolution in childhood acute lymphoblastic leukemia. *Nat Immunol* (2015) 16:766–74. doi: 10.1038/ni.3160

 Schäfer D, Olsen M, Lähnemann D, Stanulla M, Slany R, Schmiegelow K, et al. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNAbased GIPFEL screening. *Blood* (2018) 131:821–6. doi: 10.1182/blood-2017-09-808402

6. Ford AM, Colman S, Greaves M. Covert pre-leukaemic clones in healthy co-twins of patients with childhood acute lymphoblastic leukaemia. *Leukemia* (2023) 37:47–52. doi: 10.1038/s41375-022-01756-1

 Marcotte EL, Ritz B, Cockburn M, Yu F, Heck JE. Exposure to infections and risk of leukemia in young children. *Cancer Epidemiol Biomarkers Prev* (2014) 23:1195–203. doi: 10.1158/1055-9965.EPI-13-1330

8. Schmiegelow K, Vestergaard T, Nielsen SM, Hjalgrim H. Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis. *Leukemia* (2008) 22:2137–41. doi: 10.1038/leu.2008.212

9. Vogl SE, Worda C, Egarter C, Bieglmayer C, Szekeres T, Huber J, et al. Mode of delivery is associated with maternal and fetal endocrine stress response. *BJOG* (2006) 113:441-5. doi: 10.1111/j.1471-0528.2006.00865.x

10. Thomas S, Izard J, Walsh E, Batich K, Chongsathidkiet P, Clarke G, et al. The host microbiome regulates and maintains human health: A primer and perspective for non-microbiologists. *Cancer Res* (2017) 77:1783–812. doi: 10.1158/0008-5472.CAN-16-2929

11. Heitzer MD, Wolf IM, Sanchez ER, Witchel SF, DeFranco DB. Glucocorticoid receptor physiology. *Rev Endocr Metab Disord* (2007) 8:321–30. doi: 10.1007/s11154-007-9059-8

12. Papadimitriou A, Priftis KN. Regulation of the hypothalamic-pituitary-adrenal axis. *Neuroimmunomodulation* (2009) 16:265–71. doi: 10.1159/000216184

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2023.1274131/ full#supplementary-material

13. Hu X, Deng S, Luo L, Jiang Y, Ge H, Yin F, et al. GLCCI1 deficiency induces glucocorticoid resistance via the competitive binding of IRF1:GRIP1 and IRF3:GRIP1 in asthma. *Front Med (Lausanne)* (2021) 8:686493. doi: 10.3389/fmed.2021.686493

14. Tantisira KG, Lasky-Su J, Harada M, Murphy A, Litonjua AA, Himes BE, et al. Genomewide association between GLCCI1 and response to glucocorticoid therapy in asthma. *N Engl J Med* (2011) 365:1173–83. doi: 10.1056/NEJMoa0911353

15. Park H-K, Chon J, Park HJ, Chung J-H, Baik HH. Association between two promoter polymorphisms (rs1893219 and rs1893220) of MC2R gene and intracerebral hemorrhage in Korean population. *Neurosci Lett* (2015) 602:1–5. doi: 10.1016/j.neulet.2015.06.032

16. Duong-Thi-Ly H, Nguyen-Thi-Thu H, Nguyen-Hoang L, Nguyen-Thi-Bich H, Craig TJ, Duong-Quy S. Effects of genetic factors to inhaled corticosteroid response in children with asthma: a literature review. *J Int Med Res* (2017) 45:1818–30. doi: 10.1177/0300060516683877

17. Pombo-de-Oliveira MSEMiLI Study Group, , Petridou ET, Karalexi MA, Junqueira MER, Braga FHP, et al. The interplay of cesarean-section delivery and first-birth order as risk factors in acute lymphoblastic leukemia. *Cancer Epidemiol Biomarkers Prev* (2023) 32:371–9. doi: 10.1158/1055-9965.EPI-22-0664

18. Infante-Rivard C. Diagnostic x rays, DNA repair genes and childhood acute lymphoblastic leukemia. *Health Phys* (2003) 85:60–4. doi: 10.1097/00004032-200307000-00012

19. Khoury MJ, Flanders WD. Nontraditional epidemiologic approaches in the analysis of gene-environment interaction: case-control studies with no controls! *Am J Epidemiol* (1996) 144:207–13. doi: 10.1093/oxfordjournals.aje.a008915

20. Andersson T, Alfredsson L, Källberg H, Zdravkovic S, Ahlbom A. Calculating measures of biological interaction. *Eur J Epidemiol* (2005) 20:575–9. doi: 10.1007/s10654-005-7835-x

21. Zadik Z. Adrenal insufficiency in very low birth weight infants. J Pediatr Endocrinol Metab (2010) 23:1-2. doi: 10.1515/JPEM.2010.23.1-2.1

22. Flom JD, Chiu Y-HM, Hsu H-HL, Devick KL, Brunst KJ, Campbell R, et al. Maternal lifetime trauma and birthweight: effect modification by *in utero* cortisol and child sex. *J Pediatr* (2018) 203:301–8. doi: 10.1016/j.jpeds.2018.07.069

23. Ding Y-X, Zou L-P, He B, Yue W-H, Liu Z-L, Zhang D. ACTH receptor (MC2R) promoter variants associated with infantile spasms modulate MC2R expression and responsiveness to ACTH. *Pharmacogenet Genomics* (2010) 20:71–6. doi: 10.1097/FPC.0b013e328333a172

24. Barros FC, Neto D de LR, Villar J, Kennedy SH, Silveira MF, Diaz-Rossello JL, et al. Caesarean sections and the prevalence of preterm and early-term births in Brazil:

secondary analyses of national birth registration. BMJ Open (2018) 8:e021538. doi: 10.1136/bmjopen-2018-021538

25. Schneider MO, Hübner T, Pretscher J, Goecke TW, Schwitulla J, Häberle L, et al. Genetic variants in the glucocorticoid pathway genes and birth weight. *Arch Gynecol Obstet* (2021) 303:427–34. doi: 10.1007/s00404-020-05761-6

26. Gage TB, Fang F, O'Neill E, Dirienzo G. Maternal education, birth weight, and infant mortality in the United States. *Demography* (2013) 50:615–35. doi: 10.1007/s13524-012-0148-2

27. Ruiz M, Goldblatt P, Morrison J, Kukla L, Švancara J, Riitta-Järvelin M, et al. Mother's education and the risk of preterm and small for gestational age birth: a DRIVERS meta-analysis of 12 European cohorts. *J Epidemiol Community Health* (2015) 69:826–33. doi: 10.1136/jech-2014-205387

28. Laksono AD, Wulandari RD, Ibad M, Kusrini I. The effects of mother's education on achieving exclusive breastfeeding in Indonesia. *BMC Public Health* (2021) 21:14. doi: 10.1186/s12889-020-10018-7

29. Wadsby M, Nelson N, Ingemansson F, Samuelsson S, Leijon I. Behaviour problems and cortisol levels in very-low-birth-weight children. *Nord J Psychiatry* (2014) 68:626–32. doi: 10.3109/08039488.2014.907341

30. Stoye DQ, Boardman JP, Osmond C, Sullivan G, Lamb G, Black GS, et al. Saliva cortisol diurnal variation and stress responses in term and preterm infants. *Arch Dis Child Fetal Neonatal Ed* (2022) 107:558–64. doi: 10.1136/archdischild-2021-321593

31. Feng W, Pu W, Li J, Yuan Y, Yan M, Yuan S, et al. The GLCCI1 rs37973 variant and the efficacy of inhaled corticosteroids in the treatment of asthma: A meta-analysis. *Clin Respir J* (2023) 17:568–79. doi: 10.1111/crj.13627

32. Bergeron BP, Diedrich JD, Zhang Y, Barnett KR, Dong Q, Ferguson DC, et al. Epigenomic profiling of glucocorticoid responses identifies cis-regulatory disruptions impacting steroid resistance in childhood acute lymphoblastic leukemia. *Leukemia* (2022) 36:2374–83. doi: 10.1038/s41375-022-01685-z

33. Hu C-P, Xun Q-F, Li X-Z, Hu X-Y, Qin L, He R-X, et al. Effects of glucocorticoid-induced transcript 1 gene deficiency on glucocorticoid activation in asthmatic mice. *Chin Med J (Engl)* (2018) 131:2817–26. doi: 10.4103/0366-6999.246061

34. Kiuchi Z, Nishibori Y, Kutsuna S, Kotani M, Hada I, Kimura T, et al. GLCCI1 is a novel protector against glucocorticoid-induced apoptosis in T cells. *FASEB J* (2019) 33:7387–402. doi: 10.1096/fj.201800344RR